Work

Ferroptosis in cancer cells triggers PGE2 production for tumour immune escape

Year: 2026
Type: article
Abstract: Ferroptosis, a form of cell death induced by overwhelming membrane lipid peroxidation, is a vulnerability of many cancers, including cancers resistant to current molecular and immune-based therapies 1–7 . Triggering of ferroptosis therefore provides an opportunity to achieve elimination of difficult-to-treat cancers 1–4,8,9 . Studies in mouse cancer models have demonstrated that anticancer immunity, mediated by dendritic cells (DCs) and CD8 + T cells, is essential for effective tumour eradication by ferroptosis-inducing strategies 10–13 . However, ferroptotic cells limit this response 8–10,14 , resulting in immune escape and tumour growth through mechanisms that remain unclear. Here we demonstrate that ferroptotic cancer cells activate a molecular program resulting in aberrant production of prostaglandin E 2 (PGE 2 ), which limits the stimulation of anticancer CD8 + T cell responses by type 1 conventional DCs (cDC1s), thereby promoting immune escape. In ferroptotic cancer cells, lipid peroxidation-mediated membrane permeabilization enables Ca 2+ influx, which activates p38 MAPK signalling and thereby drives PGE 2 production. This signalling axis is uncoupled from cancer cell death and can be targeted to selectively interfere with immune-inhibitory PGE 2 production while preserving ferroptotic cancer cell elimination. In the context of cancer cell ferroptosis, ablation of PGE 2 production or disrupting PGE 2 signalling restores cDC1-mediated anticancer CD8 + T cell responses and leads to effective tumour elimination. Our findings identify a key mechanism that limits antitumour immunity and prevents tumour elimination upon ferroptosis induction in cancer cells, which could be exploited for cancer therapy.
Source: Nature
Language: English
Subfield: Cancer Research
Open Access status: hybrid
Estimated APC paid: $12,690
OpenAlex ID: W7236198088
FWCI:
Cites: 51
Cited by:
Related to: 10